Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2016. The document serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons, specifically detailing changes in their interests in the Company's Ordinary Shares and American Depositary Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting share allocation details for Non-Executive Directors.
Material Changes
On December 31, 2015, Non-Executive Directors were provisionally allocated awards over Ordinary Shares and ADSs through the annual reinvestment of dividends paid throughout 2015. These allocations were calculated using an average price of £13.83 per Ordinary Share and $40.98 per ADS. The Company and Directors were informed of these allocations on January 4, 2016.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document strictly addresses compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) regarding director share transactions.
Investor Verification Points
- Verify the specific number of Ordinary Shares and ADSs allocated to each Non-Executive Director as listed in the filing.
- Confirm the average share prices (£13.83 for Ordinary Shares and $40.98 for ADSs) used for the 2015 dividend reinvestment calculation.
- Review the full list of Non-Executive Directors receiving allocations to ensure completeness against the Company's current board composition.